Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIP chemotherapy + nimotuzumab + toripalimab as neoadjuvant therapy in locally advanced penile cancer
ChiCTR2000034375Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, ifosfamide, cisplatin, nimotuzumab and toripalimab in penile squamous cell carcinoma (PSCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Pathologically Complete Response Rate. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
paclitaxelifosfamidecisplatinnimotuzumabtoripalimab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on ChiCTR2000034375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034375.